Trial Profile
Post-Marketing Surveillance of Symbenda Injection (Bendamustine Hydrochloride) in Korean Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jan 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary)
- Indications Breast cancer; Cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Eisai Korea
- 25 Jan 2021 Status changed from active, no longer recruiting to completed.
- 01 Apr 2020 Planned End Date changed from 1 Jun 2020 to 1 Apr 2020.
- 01 Apr 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Apr 2020.